Redox-Responsive Comparison of Diselenide and Disulfide Core-Cross-Linked Micelles for Drug Delivery Application
In this study, diselenide (Se–Se) and disulfide (S–S) redox-responsive core-cross-linked (CCL) micelles were synthesized using poly(ethylene oxide)<sub<2k</sub<-<i<b</i<-poly(furfuryl methacrylate)<sub<1.5k</sub< (PEO<sub<2k</sub<-<i<b</i<-PFMA<sub<1.5k</sub<), and their redox sensitivity was compared. A single electron transfer-living radical polymerization technique was used to prepare PEO<sub<2k</sub<-<i<b</i<-PFMA<sub<1.5k</sub< from FMA monomers and PEO<sub<2k</sub<-Br initiators. An anti-cancer drug, doxorubicin (DOX), was incorporated into PFMA hydrophobic parts of the polymeric micelles, which were then cross-linked with maleimide cross-linkers, 1,6-bis(maleimide) hexane, dithiobis(maleimido) ethane and diselenobis(maleimido) ethane via Diels–Alder reaction. Under physiological conditions, the structural stability of both S–S and Se–Se CCL micelles was maintained; however, treatments with 10 mM GSH induced redox-responsive de-cross-linking of S–S and Se–Se bonds. In contrast, the S–S bond was intact in the presence of 100 mM H<sub<2</sub<O<sub<2,</sub< while the Se–Se bond underwent de-crosslinking upon the treatment. DLS studies revealed that the size and PDI of (PEO<sub<2k</sub<-<i<b</i<-PFMA<sub<1.5k</sub<-Se)<sub<2</sub< micelles varied more significantly in response to changes in the redox environment than (PEO<sub<2k</sub<-<i<b</i<-PFMA<sub<1.5k</sub<-S)<sub<2</sub< micelles. In vitro release studies showed that the developed micelles had a lower drug release rate at pH 7.4, whereas a higher release was observed at pH 5.0 (tumor environment). The micelles were non-toxic against HEK-293 normal cells, which revealed that they could be safe for use. Nevertheless, DOX-loaded S–S/Se–Se CCL micelles exhibited potent cytotoxicity against BT-20 cancer cells. Based on these results, the (PEO<sub<2k</sub<-<i<b</i<-PFMA<sub<1.5k-</sub<Se)<sub<2</sub< micelles can be more sensitive drug carriers than (PEO<sub<2k</sub<-<i<b</i<-PFMA<sub<1.5k</sub<-S)<sub<2</sub< micelles..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
---|---|
Enthalten in: |
Pharmaceutics - 15(2023), 4, p 1159 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sonyabapu Yadav [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
Core-cross-linked micelles |
---|
doi: |
10.3390/pharmaceutics15041159 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ089791878 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ089791878 | ||
003 | DE-627 | ||
005 | 20240413040518.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230505s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/pharmaceutics15041159 |2 doi | |
035 | |a (DE-627)DOAJ089791878 | ||
035 | |a (DE-599)DOAJ1ba716d0d5534c94b01c1d454a0fed2e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RS1-441 | |
100 | 0 | |a Sonyabapu Yadav |e verfasserin |4 aut | |
245 | 1 | 0 | |a Redox-Responsive Comparison of Diselenide and Disulfide Core-Cross-Linked Micelles for Drug Delivery Application |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a In this study, diselenide (Se–Se) and disulfide (S–S) redox-responsive core-cross-linked (CCL) micelles were synthesized using poly(ethylene oxide)<sub<2k</sub<-<i<b</i<-poly(furfuryl methacrylate)<sub<1.5k</sub< (PEO<sub<2k</sub<-<i<b</i<-PFMA<sub<1.5k</sub<), and their redox sensitivity was compared. A single electron transfer-living radical polymerization technique was used to prepare PEO<sub<2k</sub<-<i<b</i<-PFMA<sub<1.5k</sub< from FMA monomers and PEO<sub<2k</sub<-Br initiators. An anti-cancer drug, doxorubicin (DOX), was incorporated into PFMA hydrophobic parts of the polymeric micelles, which were then cross-linked with maleimide cross-linkers, 1,6-bis(maleimide) hexane, dithiobis(maleimido) ethane and diselenobis(maleimido) ethane via Diels–Alder reaction. Under physiological conditions, the structural stability of both S–S and Se–Se CCL micelles was maintained; however, treatments with 10 mM GSH induced redox-responsive de-cross-linking of S–S and Se–Se bonds. In contrast, the S–S bond was intact in the presence of 100 mM H<sub<2</sub<O<sub<2,</sub< while the Se–Se bond underwent de-crosslinking upon the treatment. DLS studies revealed that the size and PDI of (PEO<sub<2k</sub<-<i<b</i<-PFMA<sub<1.5k</sub<-Se)<sub<2</sub< micelles varied more significantly in response to changes in the redox environment than (PEO<sub<2k</sub<-<i<b</i<-PFMA<sub<1.5k</sub<-S)<sub<2</sub< micelles. In vitro release studies showed that the developed micelles had a lower drug release rate at pH 7.4, whereas a higher release was observed at pH 5.0 (tumor environment). The micelles were non-toxic against HEK-293 normal cells, which revealed that they could be safe for use. Nevertheless, DOX-loaded S–S/Se–Se CCL micelles exhibited potent cytotoxicity against BT-20 cancer cells. Based on these results, the (PEO<sub<2k</sub<-<i<b</i<-PFMA<sub<1.5k-</sub<Se)<sub<2</sub< micelles can be more sensitive drug carriers than (PEO<sub<2k</sub<-<i<b</i<-PFMA<sub<1.5k</sub<-S)<sub<2</sub< micelles. | ||
650 | 4 | |a Diels–Alder reaction | |
650 | 4 | |a disulfide | |
650 | 4 | |a diselenide | |
650 | 4 | |a core-cross-linked micelles | |
650 | 4 | |a redox-responsive | |
650 | 4 | |a drug delivery | |
653 | 0 | |a Pharmacy and materia medica | |
700 | 0 | |a Kalyan Ramesh |e verfasserin |4 aut | |
700 | 0 | |a Obireddy Sreekanth Reddy |e verfasserin |4 aut | |
700 | 0 | |a Viswanathan Karthika |e verfasserin |4 aut | |
700 | 0 | |a Parveen Kumar |e verfasserin |4 aut | |
700 | 0 | |a Sung-Han Jo |e verfasserin |4 aut | |
700 | 0 | |a Seong II Yoo |e verfasserin |4 aut | |
700 | 0 | |a Sang-Hyug Park |e verfasserin |4 aut | |
700 | 0 | |a Kwon Taek Lim |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Pharmaceutics |d MDPI AG, 2010 |g 15(2023), 4, p 1159 |w (DE-627)DOAJ000114154 |x 19994923 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2023 |g number:4, p 1159 |
856 | 4 | 0 | |u https://doi.org/10.3390/pharmaceutics15041159 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/1ba716d0d5534c94b01c1d454a0fed2e |z kostenfrei |
856 | 4 | 0 | |u https://www.mdpi.com/1999-4923/15/4/1159 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1999-4923 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |d 15 |j 2023 |e 4, p 1159 |